Tarsus Pharmaceuticals logo

Tarsus PharmaceuticalsNASDAQ: TARS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 October 2020

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.79 B
-8%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-11%vs. 3y high
89%vs. sector
-82%vs. 3y high
81%vs. sector

Price

after hours | Tue, 19 Nov 2024 21:11:30 GMT
$46.87+$2.24(+5.02%)

Dividend

No data over the past 3 years
$48.12 M$57.12 M
$48.12 M-$23.42 M

Analysts recommendations

Institutional Ownership

TARS Latest News

Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
zacks.com18 November 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
zacks.com13 November 2024 Sentiment: POSITIVE

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
globenewswire.com17 October 2024 Sentiment: POSITIVE

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids

Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
seekingalpha.com20 September 2024 Sentiment: POSITIVE

Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth.

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
globenewswire.com28 August 2024 Sentiment: POSITIVE

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in Boston, MA, on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
seekingalpha.com20 August 2024 Sentiment: POSITIVE

Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable segment alone. TARS has promising data in trials for various conditions, including Lyme disease and Meibomian gland disease, with potential preventive and therapeutic benefits.

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - Barclays Eddie Hickman - Guggenheim Securities Operator Good afternoon. And welcome to the Tarsus' Second Quarter 2024 Financial Results Conference Call.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago.

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
globenewswire.com29 July 2024 Sentiment: POSITIVE

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update.

Tarsus to Participate in Upcoming Investor Conferences
globenewswire.com29 May 2024 Sentiment: POSITIVE

IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following conferences:

  • 1(current)

What type of business is Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

What sector is Tarsus Pharmaceuticals in?

Tarsus Pharmaceuticals is in the Healthcare sector

What industry is Tarsus Pharmaceuticals in?

Tarsus Pharmaceuticals is in the Biotechnology industry

What country is Tarsus Pharmaceuticals from?

Tarsus Pharmaceuticals is headquartered in United States

When did Tarsus Pharmaceuticals go public?

Tarsus Pharmaceuticals initial public offering (IPO) was on 16 October 2020

What is Tarsus Pharmaceuticals website?

https://www.tarsusrx.com

Is Tarsus Pharmaceuticals in the S&P 500?

No, Tarsus Pharmaceuticals is not included in the S&P 500 index

Is Tarsus Pharmaceuticals in the NASDAQ 100?

No, Tarsus Pharmaceuticals is not included in the NASDAQ 100 index

Is Tarsus Pharmaceuticals in the Dow Jones?

No, Tarsus Pharmaceuticals is not included in the Dow Jones index

When was Tarsus Pharmaceuticals the previous earnings report?

No data

When does Tarsus Pharmaceuticals earnings report?

The next expected earnings date for Tarsus Pharmaceuticals is 27 February 2025